Startseite>>Signaling Pathways>> Apoptosis>> Bcl-2 Family>>WEHI-539 hydrochloride

WEHI-539 hydrochloride

Katalog-Nr.GC13317

WEHI-539 Hydrochlorid ist ein selektiver Inhibitor von Bcl-XL mit einem IC50 von 1,1 nM.

Products are for research use only. Not for human use. We do not sell to patients.

WEHI-539 hydrochloride Chemische Struktur

Cas No.: 2070018-33-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
301,00 $
Auf Lager
5mg
146,00 $
Auf Lager
10mg
186,00 $
Auf Lager
50mg
686,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

WEHI-539 hydrochloride is a small-molecule inhibitor of BCL XL with IC50 value of 1.1 nM [1].

WEHI-539 was designed as a BCL-XL inhibitor with high affinity. It interacted with the binding groove of BCL-XL with Kd value of 0.6 nM. In MEF cells lacking MCL-1, WEHI-539 induced apoptosis which was evidenced by the release of mitochondrial cytochrome c and caspase-3 processing. In BCL-XL overexpressed MEF cells, WEHI-539 showed EC50 value of 0.48 μM. WEHI-539 also significantly induced apoptosis of the platelets purified from mice. Besides that, WEHI-539 cannot kill MEF cells lacking BAK because the cell death mediator BAK is regulated by BCL-XL and MCL-1. [1].

Reference:
[1].  Lessene G, Czabotar PE, Sleebs BE, et al. Structure-guided design of a selective BCL-XL inhibitor. Nature chemical biology, 2013, 9(6): 390-397.

Bewertungen

Review for WEHI-539 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WEHI-539 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.